Navigation Links
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
Date:6/4/2008

se and central sensitization. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether any preclinical studies or clinical trials conducted in the future, will prove successful, and if successful, whether the results can be replicated. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2007 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is likely to change and speak only as of the date hereof.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda Chiger

Rx Communications

917-322-2569

rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
3. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
9. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
10. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
11. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW YORK, Dec. 9 MR, CT, PET - we,ve ... these hi-tech imaging scans? Here,s more on what questions you ... hood with a medical scan. , Listen to this report from ... a division of The NewsMarket. Registered journalists can access video, ...
... , , , INDIANAPOLIS, Dec. 9 ... leading provider of managed voice, Internet and data networking solutions ... that Indiana Blood Center has selected the company to provide ... 11 locations located throughout Indiana. Indiana Blood Center will also ...
Cached Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2
(Date:7/9/2014)... low back pain are not linked to weather conditions ... precipitation. Findings published in Arthritis Care & Research ... (ACR), indicate that the risk of low back pain ... but was not clinically significant. , According to ... back pain at some point in their life, making ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... new health reform in China have been released after ... the most important policies ,The National Essential Drug System,. ... high cost of drugs in China through a government-initiated ... that cover a wide range of diseases and meet ...
... today a partnership with Medical Hair Restoration. , ... ... LLC, an online lead generation company, announced today a partnership with ... property, USHairReplacement.com, we wanted to partner with one of the industry ...
... ScarArt is a specially designed temporary tattoo to fit horizontal tummy tuck ... It is waterproof, smear proof and was designed to last 1-3 days. ... ... TX (PRWEB) May 21, 2009 -- ScarArt, an innovative new company specializing ...
... source of information on multiple sclerosis medications and the financial ... ... 21, 2009 -- NeedyMeds, a national nonprofit, added a new resource page ... The page is a multiple sclerosis-specific source of help for those looking ...
... OAK BROOK, Ill., May 21 The University HealthSystem ... 3-year agreement with Mzinga, Inc. for on-demand learning solutions. ... and became effective on March 1, 2009, positions Mzinga ... UHC member hospitals throughout the United States, building on ...
... be associated with obesity. But a new study published ... that the disorder is widely undiagnosed among obese individuals with ... symptoms, but were never diagnosed. , For those with untreated ... existing research shows that it can also mean an increased ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3Health News:More than a bad night's sleep 2
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
... tubes are available in two ... contains a clotting activator and ... where serum is required for ... tube is suitable where the ...
Inquire...
Medicine Products: